Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
Opus Genetics (Nasdaq: IRD) has announced its participation in four major medical and industry conferences in October 2025, where it will present clinical results from its pipeline programs. The company will showcase data from two key programs: the OPGx-LCA5 gene therapy for Leber congenital amaurosis type 5 (LCA5) and Phentolamine Ophthalmic Solution 0.75% (POS).
The presentations will include three-month pediatric and 18-month adult clinical data from the Phase 1/2 trial of OPGx-LCA5, as well as pivotal Phase 3 data from the LYNX-2 trial in keratorefractive patients. The company will present at the Cell and Gene Meeting on the Mesa, Fierce Biotech Week, American Academy of Optometry Annual Meeting, and Eyecelerator @ American Academy of Ophthalmology.
Opus Genetics (Nasdaq: IRD) ha annunciato la sua partecipazione a quattro importanti conferenze mediche e di settore in ottobre 2025, dove presenterà i risultati clinici dai suoi programmi in pipeline. L'azienda metterà in evidenza dati provenienti da due programmi chiave: la terapia genica OPGx-LCA5 per la Leber congenita amaurosi di tipo 5 (LCA5) e la Phentolamine Ophthalmic Solution 0,75% (POS).
Le presentazioni includeranno dati clinici pediatrici a tre mesi e adulti a 18 mesi dal trial di Fase 1/2 di OPGx-LCA5, nonché dati chiave di Fase 3 dallo studio LYNX-2 su pazienti keratorefrattivi. L'azienda parteciperà al Cell and Gene Meeting on the Mesa, Fierce Biotech Week, American Academy of Optometry Annual Meeting e Eyecelerator @ American Academy of Ophthalmology.
Opus Genetics (Nasdaq: IRD) ha anunciado su participación en cuatro conferencias médicas e industriales importantes en octubre de 2025, donde presentará resultados clínicos de su cartera. La empresa mostrará datos de dos programas clave: la terapia génica OPGx-LCA5 para LCA5 y la Phentolamine Ophthalmic Solution 0,75% (POS).
Las presentaciones incluirán datos clínicos pediátricos a tres meses y adultos a 18 meses del ensayo de Fase 1/2 de OPGx-LCA5, así como datos de fase 3 cruciales del estudio LYNX-2 en pacientes keratorefrácticos. La compañía presentará en el Cell and Gene Meeting on the Mesa, la Fierce Biotech Week, la American Academy of Optometry Annual Meeting y Eyecelerator @ American Academy of Ophthalmology.
Opus Genetics (Nasdaq: IRD)는 2025년 10월에 네 차례의 주요 의료 및 업계 회의에 참여하여 파이프라인 프로그램의 임상 결과를 발표할 예정이라고 발표했습니다. 두 가지 주요 프로그램의 데이터를 선보일 예정입니다: OPGx-LCA5 유전자 치료제는 LCA5를 위한 치료이고, Phentolamine Ophthalmic Solution 0.75% (POS)도 포함됩니다.
발표에는 OPGx-LCA5의 1/2상 임상시험에서 3개월 소아 및 18개월 성인 임상 데이터와 LYNX-2 연구에서 각막 굴절 환자를 대상으로 한 3상 데이터가 포함됩니다. 회사는 Cell and Gene Meeting on the Mesa, Fierce Biotech Week, American Academy of Optometry Annual Meeting, Eyecelerator @ American Academy of Ophthalmology에서 발표할 예정입니다.
Opus Genetics (Nasdaq: IRD) a annoncé sa participation à quatre grandes conférences médicales et industrielles en octobre 2025, où elle présentera les résultats cliniques de son portefeuille. L'entreprise mettra en avant des données de deux programmes clés : la thérapie génique OPGx-LCA5 pour la LCA5 et la Phentolamine Ophthalmic Solution 0,75% (POS).
Les présentations comprendront des données cliniques pédiatriques à trois mois et des adultes à 18 mois issues de l'essai de Phase 1/2 d'OPGx-LCA5, ainsi que des données pivotantes de Phase 3 de l'essai LYNX-2 chez des patients keratorefractiv es. L'entreprise présentera au Cell and Gene Meeting on the Mesa, à Fierce Biotech Week, à l'American Academy of Optometry Annual Meeting et à Eyecelerator @ American Academy of Ophthalmology.
Opus Genetics (Nasdaq: IRD) hat seine Teilnahme an vier großen medizinischen und Branchenkonferenzen im Oktober 2025 angekündigt, wo es klinische Ergebnisse aus seinen Pipeline-Programmen präsentieren wird. Das Unternehmen wird Daten aus zwei Schlüsselprogrammen vorstellen: die OPGx-LCA5-Gentherapie für LCA5 und die Phentolamine Ophthalmic Solution 0,75% (POS).
Die Präsentationen umfassen dreimonatige pädiatrische und 18-monatige erwachsene klinische Daten aus der Phase-1/2-Studie von OPGx-LCA5 sowie schlüssige Phase-3-Daten aus der LYNX-2-Studie bei keratorefraktiven Patienten. Das Unternehmen wird beim Cell and Gene Meeting on the Mesa, der Fierce Biotech Week, der American Academy of Optometry Annual Meeting und Eyecelerator @ American Academy of Ophthalmology präsentieren.
Opus Genetics (Nasdaq: IRD) أعلنت عن مشاركتها في أربع مؤتمرات طبية وصناعية كبرى في أكتوبر 2025، حيث ستعرض نتائج سريرية من برامجها في خط أنابيبها. ستعرض الشركة بيانات من برنامجين رئيسيين: العلاج الجيني OPGx-LCA5 لـ LCA5 وPhentolamine Ophthalmic Solution 0.75% (POS).
ستشمل العروض بيانات سريرية للأطفال حتى ثلاثة أشهر وبالغين حتى 18 شهراً من تجربة المرحلة 1/2 لOPGx-LCA5، إضافة إلى بيانات المرحلة 3 الحاسمة من تجربة LYNX-2 لدى مرضى keratorefractive. ستقدم الشركة عروضها في Cell and Gene Meeting on the Mesa، Fierce Biotech Week، American Academy of Optometry Annual Meeting وEyecelerator @ American Academy of Ophthalmology.
Opus Genetics（纳斯达克：IRD）已宣布将在2025年10月参加四场重要的医学及行业会议，在这些会议上展示其管线项目的临床结果。公司将展示两个关键项目的数据：OPGx-LCA5基因治疗用于LCA5，以及Phentolamine Ophthalmic Solution 0.75%（POS）。“
演讲将包括OPGx-LCA5 1/2期临床试验的3个月儿科和18个月成人数据，以及LYNX-2试验在角膜屈光患者中的关键3期数据。公司将于Cell and Gene Meeting on the Mesa、Fierce Biotech Week、American Academy of Optometry Annual Meeting、Eyecelerator @ American Academy of Ophthalmology进行发言。
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it will present the positive clinical results from both its IRD gene therapy and Phentolamine Ophthalmic Solution
“These upcoming presentations highlight the strong momentum across our pipeline, from advancing OPGx-LCA5 for patients living with an LCA5 IRD to sharing pivotal Phase 3 data from LYNX-2 in keratorefractive patients with visual disturbances under mesopic, low-contrast conditions,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “We look forward to engaging with the gene therapy, ophthalmology, and investor communities at these key meetings.”
Conference Participation Details:
Cell and Gene Meeting on the Mesa
- Presentation Title: Transformative Gene Therapies for the Treatment of Rare Inherited Retinal Diseases
- Presentation Content: Three-month pediatric and 18-month adult clinical data from the Phase 1/2 trial of OPGx-LCA5 in patients with Leber congenital amaurosis type 5 (LCA5)
- Date/Time: Monday, October 6, 2025, 9:15–9:30 am MT
- Presenter: George Magrath, M.D., Chief Executive Officer, Opus Genetics
- Location: Arizona Biltmore, Phoenix, AZ
Fierce Biotech Week
- Fireside Chat: Investing with Intention – How Early Vision and Partnership Shaped Opus Genetics
- Date/Time: Wednesday, October 8, 2025, 12:15–12:45 pm ET
- Speakers: Ben Yerxa, Ph.D., President, Opus Genetics and Christy Shaffer, Ph.D., General Partner, Hatteras Venture Partners
- Location: Encore Boston Harbor Hotel, Boston, MA
American Academy of Optometry Annual Meeting 2025
- Poster Presentation: LYNX-2: A Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution in Post-Keratorefractive Surgery Subjects with Decreased Mesopic Visual Acuity
- Date: Thursday, October 9, 4:30 PM–6:30 pm ET
- Presenter: Marc Bloomenstein, O.D.
- Location: Halls B2/C, Thomas M. Menino Convention & Exhibition Center, Boston, MA
Eyecelerator @ American Academy of Ophthalmology (AAO)
- Presentation Title: Transformative Gene Therapies for the Treatment of Rare Inherited Retinal Diseases
- Presentation Content: Three-month pediatric and 18-month adult clinical data from the OPGx-LCA5 Phase 1/2 trial
- Session Date/Time: Thursday, October 16, 2025, 1:15–2:45 pm ET
- Presenter: Sally Tucker, Ph.D., Senior Vice President of Clinical Development, Opus Genetics
- Location: Orange County Convention Center, Orlando, FL
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution
Contacts
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
FAQ
When and where will Opus Genetics (IRD) present its OPGx-LCA5 gene therapy data?
What clinical data will Opus Genetics present for its LCA5 gene therapy program?
Where will Opus Genetics present its LYNX-2 Phase 3 trial results?
Who are the key speakers presenting at the Fierce Biotech Week fireside chat?
